Fig. 2: Doxorubicin treatment increases SAT1 expression and tumor production of diacetylspermine, which is sustained following the final dose. | npj Precision Oncology

Fig. 2: Doxorubicin treatment increases SAT1 expression and tumor production of diacetylspermine, which is sustained following the final dose.

From: Pharmacometabolomics reveals urinary diacetylspermine as a biomarker of doxorubicin effectiveness in triple negative breast cancer

Fig. 2

a Plasma diacetylspermine and tissue urea cycle (b), polyamine (c) and acetylated polyamine (d) metabolites from TM97 and TM98 TNBC-PDX mice treated with vehicle (5% dextrose, IV) or doxorubicin (DOXO, 2 mg/kg, IV). e mRNA expression of polyamine pathway enzymes in TM97 and TM98 TNBC-PDX mice treated with vehicle or doxorubicin. f TM98 mice treated with vehicle or doxorubicin and placed in metabolic cages for urine collection as indicated. g Urine diacetylspermine normalized to tumor volume. Data are presented as mean ± s.e.m. n = 8–9 (a–e), n = 6 (f, g). Significance was determined by one-way ANOVA with Tukey’s test or two-way repeated measures ANOVA with Sidak’s correction, *P < 0.05, **P < 0.01, ***P < 0.01, ****P < 0.0001 vs TM97; #P < 0.05, ##P < 0.01, ####P < 0.0001 vs TM98 control. Plasma concentrations below the limit of quantification (LOQ) were calculated as LOQ/2.

Back to article page